Phase 3 N=203 Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
Liver Transplantation
Primary: Calculated Glomerular Filtration Rate (cGFR) — 87.9; 84.1 mL/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=90 A Premarket, Prospective, Randomized, Single-Blind Study to Compare the Veriset™ Hemostatic Patch to TachoSil® as an Adjunct to Hemostasis in Subjects Undergoing Cardiovascular Surgery
Cardiac Surgical Procedures · Hemorrhage
Primary: Time to Hemostasis (TTH) — 1.50; 3.00 minutes
N/A N=13 Proton Therapy for Unresectable Cancer (CA) of Pancreas
Pancreatic Cancer
Primary: Cumulative Incidence of grade3+ Bowel Perforation, Grade 3+ Bleeding (Ocurring Withing 1 Years) and grade4+ Nonhematologic Acute Adverse Events (Limited to Within 90…
N/A N=33 Taste Perception Pre and Post Bariatric Surgery
Morbid Obesity
Primary: Changes on Taste Detection Thresholds After Bariatric Surgery-induced Weight Loss (Roux-en-Y Gastric Bypass and Laparoscopic Adjustable Banding). — 7.5; 8.1; 6.5; 7.5…
N/A N=50 Study to Evaluate the Clinical Performance of the Valiant Thoracic Stent Graft With the Captivia Delivery System (Valiant Captivia) for the Treatment of Acute, Complicated Type B Aortic Dissections
Aortic Dissection
Primary: All Cause Mortality. — 4 participants
Phase 2 N=24 Varenicline and Smoking Cessation in Schizophrenia
Schizophrenia · Smoking Cessation
Primary: Smoking Abstinence - Serum/Urine Measurements — 198.67; 207; 213.8; 22.57 ng/mL — p=>0.05
N/A N=4,132 Medtronic Shock-Less Study on Physician Utilization of Shock Reduction Programming
Cardiovascular Disease
Primary: Change in Shock Reduction Programming Adoption — 13.6; 6.8; 9.0; 3.5 percentage of participants — p=<0.0001
Phase 2 N=42 Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy
Hepatocellular Carcinoma
Primary: Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab — 4.0 months
N/A N=48 A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm
Cervical Dystonia · Blepharospasm
Primary: Dose of Botulinum Toxin Used to Treat Cervical Dystonia — 444.70; 536.30 units per patient per year
Phase 1 N=18 Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid
Healthy
Primary: Total Empagliflozin: Area Under the Curve 0 to Infinity (AUC0-∞) — 2240; 3020; 3400 nmol*h/L
N/A N=26 SYSTANE® Family - Meibomian Deficiency
Dry Eye Syndrome
Primary: Number of Meibomian Glands Yielding Liquid Secretion (MGLYS) — 3.5; 4.2; 7.0; 3.9 functioning glands
N/A N=137 Laparoscopic Radiofrequency Ablation (RFA) of Symptomatic Uterine Fibroids
Uterine Fibroids · Uterine Myomas
Primary: Assessment of Menstrual Blood Flow (MBF) at 12 Months Post Procedure — 40.2; 48.8; 59.1; 67.7 Percentage of participants
Phase 4 N=15 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients
Glaucoma · Dry Eyes
Primary: Ocular Surface Staining — 1.65 units on a scale
N/A N=1,274 Timing of Planned Caesarean Section and Morbidity of the Newborn
Respiratory Disorders · Intensive Care, Neonatal
Primary: Neonatal Admission After Elective Caesarean Section — 88; 76 participants — p=0.31
N/A N=50 ENDO GIA™ Stapler With ENDO GIA™ Reload With Tri-Staple™ Technology in a Pulmonary Resection
Lung Cancer
Primary: Incidence of Prolonged Air Leaks — 5 participants